TP53 and in situ carcinoma: Carcinoma in situ (CIS) and muscle-invasive tumors (pT2–pT4) exhibit high rates of TP53 mutations, suggesting that this biomarker is an indicator of disease progression and may be a valuable predictor of more aggressive forms of BCa [25, 26].